Asahi Intecc Co Ltd (JP:7747)
:7747
Top Page
Asahi Intecc Co
(7747)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥3,807.00
▲(8.99% Upside)
Action:DowngradedDate:11/22/25
Asahi Intecc Co's overall stock score is driven by strong financial performance, highlighted by robust revenue growth and efficient cash flow management. However, technical indicators suggest overbought conditions, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.
Positive Factors
Sustained revenue growth & healthy margins
The company reported a 17.7% revenue increase alongside a high gross margin (65.18%) and solid net margin (10.61%). These durable top-line growth and margin levels indicate strong product demand and pricing power in core devices, supporting reinvestment in R&D and stable long-term profitability.
Negative Factors
Pressure on operating margins
EBIT and EBITDA margins have edged down, signaling rising cost pressure or mix shifts. Persistent margin compression would erode cash flow generation and ROE over time unless offset by price increases, efficiency gains, or higher-margin product mix improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth & healthy margins
The company reported a 17.7% revenue increase alongside a high gross margin (65.18%) and solid net margin (10.61%). These durable top-line growth and margin levels indicate strong product demand and pricing power in core devices, supporting reinvestment in R&D and stable long-term profitability.
Read all positive factors
Asahi Intecc Co (7747) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥933.94B
Dividend Yield0.82%
Average Volume (3M)951.34K
Price to Earnings (P/E)24.3
Beta (1Y)0.87
Revenue Growth13.53%
EPS Growth-7.39%
CountryJP
Employees9,371
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding265,332,300
10 Day Avg. Volume923,580
30 Day Avg. Volume951,336
Financial Highlights & Ratios
PEG Ratio-2.51
Price to Book (P/B)4.12
Price to Sales (P/S)5.16
P/FCF Ratio19.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,200.00Price Target Upside20.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Asahi Intecc Co Business Overview & Revenue Model
Company Description
Asahi Intecc Co., Ltd. engages in the development, manufacture, and sale of medical devices in Japan, the United States, Europe, the Middle East, China, and internationally. The company provides percutaneous transluminal coronary angioplasty (PTCA...
How the Company Makes Money
Asahi Intecc primarily makes money by selling medical devices used in minimally invasive catheter-based procedures. Its core revenue stream is product sales of interventional consumables—especially guidewires and related catheter accessories—throu...
Asahi Intecc Co Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 120.03B | 107.55B | 90.10B | 77.75B | 61.51B |
| Gross Profit | 78.23B | 66.11B | 56.26B | 49.24B | 40.40B |
| EBITDA | 40.23B | 31.86B | 26.73B | 22.61B | 17.76B |
| Net Income | 12.74B | 15.81B | 13.11B | 10.86B | 9.98B |
Balance Sheet | |||||
| Total Assets | 193.19B | 191.61B | 172.64B | 155.13B | 115.43B |
| Cash, Cash Equivalents and Short-Term Investments | 54.20B | 38.66B | 36.88B | 32.32B | 21.36B |
| Total Debt | 11.52B | 8.20B | 15.87B | 13.22B | 9.13B |
| Total Liabilities | 41.83B | 39.65B | 38.34B | 33.99B | 22.48B |
| Stockholders Equity | 150.56B | 151.22B | 132.31B | 119.46B | 92.91B |
Cash Flow | |||||
| Free Cash Flow | 32.45B | 24.83B | 6.85B | 9.32B | -986.00M |
| Operating Cash Flow | 40.54B | 34.71B | 19.14B | 17.30B | 8.92B |
| Investing Cash Flow | -13.43B | -21.22B | -15.13B | -18.70B | -16.33B |
| Financing Cash Flow | -8.11B | -13.88B | -2.34B | 11.37B | 10.11B |
Asahi Intecc Co Technical Analysis
Positive
3493.00
Price Trends
3115.71
Positive
3007.80
Positive
2716.75
Positive
Market Momentum
123.20
Negative
59.98
Neutral
58.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7747, the sentiment is Positive. The current price of 3493 is above the 20-day moving average (MA) of 3376.55, above the 50-day MA of 3115.71, and above the 200-day MA of 2716.75, indicating a bullish trend. The MACD of 123.20 indicates Negative momentum. The RSI at 59.98 is Neutral, neither overbought nor oversold. The STOCH value of 58.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7747.
Asahi Intecc Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥3.15T | 25.64 | 8.98% | 1.22% | 7.68% | 10.08% | |
71 Outperform | ¥153.49B | 18.72 | ― | 2.73% | 5.10% | -26.13% | |
68 Neutral | ¥933.94B | 24.33 | 11.64% | 0.82% | 13.53% | -7.39% | |
63 Neutral | ¥241.17B | -69.02 | -2.06% | 2.66% | 5.43% | -20.67% | |
62 Neutral | ¥269.19B | 5.59 | 4.38% | 2.03% | 6.04% | 733.13% | |
59 Neutral | ¥1.69T | 38.56 | 11.34% | 1.01% | 0.42% | 34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7747
Asahi Intecc Co
3,493.00
1,338.66
62.14%
JP:4543
Terumo
2,155.50
-433.57
-16.75%
JP:7716
Nakanishi
2,849.00
1,062.05
59.43%
JP:8086
Nipro
1,626.50
379.04
30.39%
JP:7733
Olympus
1,585.00
-148.82
-8.58%
JP:7730
Mani, Inc.
1,553.00
519.18
50.22%
Asahi Intecc Co Corporate Events
Asahi Intecc Secures Exclusive Japan Rights to Nexsphere-F Embolization Agent
Apr 9, 2026
Asahi Intecc has signed an exclusive distribution agreement with South Korea’s NEXTBIOMEDICAL to sell the embolization agent Nexsphere-F in Japan, targeting use in Transcatheter Arterial Micro-Embolization procedures for chronic pain. Althou...
Asahi Intecc Lifts FY2026 Dividend Forecast with 50th Anniversary Payout
Feb 13, 2026
Asahi Intecc Co. has announced a revision to its dividend forecast for the fiscal year ending June 30, 2026, coinciding with the 50th anniversary of its establishment on July 8, 2026. The company, which specializes in advanced medical device compo...
Asahi Intecc Lifts FY2026 Profit Outlook on Strong Demand and Margin Gains
Feb 13, 2026
Asahi Intecc revised its full-year consolidated earnings forecast for the fiscal year ending June 30, 2026, projecting a significant increase in operating profit driven by strong sales in both its Medical and Device businesses and favorable foreig...
Asahi Intecc Raises Full-Year Profit Outlook on Strong Medical and Device Demand
Feb 13, 2026
Asahi Intecc has sharply revised upward its full-year consolidated forecast for the fiscal year ending June 30, 2026, citing stronger-than-expected performance in both its Medical and Device divisions and favorable foreign exchange rates. The comp...
Asahi Intecc Posts Double-Digit Sales Growth on Strong Medical and Device Demand
Feb 13, 2026
Asahi Intecc Co. reported consolidated net sales of 71,266 million yen for the first half of the fiscal year ending June 2026, a year-on-year increase of 15.9 percent, driven by solid performance in both its Medical and Device divisions. The Medic...
Asahi Intecc Lifts Earnings and Dividend Outlook on Strong First-Half Results
Feb 13, 2026
Asahi Intecc reported strong results for the six months ended Dec. 31, 2025, with net sales rising 15.9% year on year to ¥71.27 billion and profit attributable to owners of parent up 40.4% to ¥17.21 billion. Operating profit jumped 40.1%...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.